Structure via PubChem · Public domain (PubChem)
clobazam
Sign in to saveAlso known as H-4723, HR-376, LM-2717, 1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-dioxo-3H-1,5-benzodiazepine, Frisium, Onfi, Urbanol
Clobazam (INN) is a long-acting benzodiazepine sold under the brand name, Frisium among others, is used as a sedative-hypnotic, anxiolytic, and anticonvulsant that was patented in 1968. Clobazam was first synthesized in 1966 and first published in 1969. It was approved in Australia in 1970 and France in 1974 for short-term anxiety management. Marketing for clobazam in the treatment of epilepsy began in 1984. The primary drug-development goal was to provide greater anxiolytic, anti-obsessive efficacy with fewer benzodiazepine-related side effects. Clobazam is a unique 1,5-benzodiazepine which i
Key facts
- Drug.image
- File:Clobazam-2D-skeletal.png
- Drug.image_class
- skin-invert-image
- Drug.width
- 200
- Drug.image2
- File:Clobazam ball-and-stick model.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 200
- Drug.tradename
- Frisium, others
- Drug.MedlinePlus
- a612008
- Drug.DailyMedID
- Clobazam
- Drug.pregnancy_AU
- C
- Drug.dependency_liability
- Very high
- Drug.addiction_liability
- High
- Drug.routes_of_administration
- By mouth, sublingual
- Drug.class
- Benzodiazepine
- Drug.ATC_prefix
- N05
- Drug.ATC_suffix
- BA09
- Drug.legal_AU
- S4
- Drug.legal_BR
- B1
via Wikipedia infobox
Chemical data
- Formula
- C16H13ClN2O2
- Molecular weight
- 300.74 g/mol
- IUPAC name
- 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione
- SMILES
- CN1C(=O)CC(=O)N(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
- InChIKey
- CXOXHMZGEKVPMT-UHFFFAOYSA-N
- XLogP
- 2.1
- Polar surface area
- 40.6 Ų
- H-bond donors
- 0
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Research
1,406 papers- Clobazam.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2007
- Corticosteroids versus clobazam for treatment of children with epileptic encephalopathy with spike-wave activation in sleep (RESCUE ESES): a multicentre randomised controlled trial.The Lancet. Neurology · 2024
- Clobazam monotherapy for focal or generalized seizures.The Cochrane database of systematic reviews · 2018
- Clobazam for treatment of epilepsy.Expert opinion on pharmacotherapy · 2012
- Clobazam monotherapy for partial-onset or generalized-onset seizures.The Cochrane database of systematic reviews · 2014
via PubMed
Wikidata facts
- Mass
- 300.066555
Show 7 more facts
- chemical formula
- C₁₆H₁₃ClN₂O₂
- canonical SMILES
- CN1C(=O)CC(=O)N(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
- World Health Organisation international non-proprietary name
- clobazam
- defined daily dose
- 20
- Commons category
- Clobazam
- MCN code
- 2933.72.10
- stylized name
- cloBAZam
Sources (7)
via Wikidata · CC0
~10 min read
Article
16 sectionsContents
- Medical uses
- Side effects
- Common
- Warnings and precautions
- Overdose
- Abuse potential and addiction
- Dependence and withdrawal
- Pharmacology
- Metabolism
- Chemistry
- History
- Society and culture
- Legal status
- See also
- References
- Further reading
Clobazam (INN) is a long-acting benzodiazepine sold under the brand name, Frisium among others, is used as a sedative-hypnotic, anxiolytic, and anticonvulsant that was patented in 1968. Clobazam was first synthesized in 1966 and first published in 1969. It was approved in Australia in 1970 and France in 1974 for short-term anxiety management. Marketing for clobazam in the treatment of epilepsy began in 1984. The primary drug-development goal was to provide greater anxiolytic, anti-obsessive efficacy with fewer benzodiazepine-related side effects. Clobazam is a unique 1,5-benzodiazepine which is used in the United States only as an anticonvulsant. It is available in other countries for the therapy of severe and disabling anxiety in addition to epilepsy. Clobazam has shown a distinct profile and addictive potential compared to the more common benzodiazepines.
In October 2011, the US Food and Drug Administration approved clobazam as an adjunctive treatment for seizures associated with Lennox–Gastaut syndrome in adults and children aged two years of age and older. In 2005, clobazam also received approval from Health Canada as an add-on therapy for generalized tonic–clonic, myoclonic, and focal impaired awareness seizures.